Get the Stockscreener App
78.47
0.60%
-0.47
After Hours:
78.47
Henry Schein Inc stock is traded at $78.47, with a volume of 944.44K.
It is down -0.60% in the last 24 hours and up +1.15% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
See More
Previous Close:
$78.94
Open:
$78.97
24h Volume:
944.44K
Relative Volume:
0.69
Market Cap:
$9.24B
Revenue:
$12.50B
Net Income/Loss:
$314.00M
P/E Ratio:
32.16
EPS:
2.44
Net Cash Flow:
$421.00M
1W Performance:
+0.50%
1M Performance:
+1.15%
6M Performance:
+8.68%
1Y Performance:
+4.93%
1-Day Range:
$78.24
$79.44
1-Week Range:
$77.53
$80.10
52-Week Range:
$60.56
$82.49
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
78.47 | 9.29B | 12.50B | 314.00M | 421.00M | 2.44 |
|
MCK
Mckesson Corporation
|
817.05 | 101.61B | 387.09B | 4.23B | 6.01B | 32.12 |
|
COR
Cencora Inc
|
352.47 | 68.24B | 321.33B | 1.57B | 3.21B | 7.9518 |
|
CAH
Cardinal Health Inc
|
206.89 | 49.53B | 234.31B | 1.61B | 4.45B | 6.6243 |
|
AHG
Akso Health Group Adr
|
1.525 | 862.25M | 2.22M | -5.63M | -1.68M | -0.24 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET - BioSpace
How Investors Are Reacting To Henry Schein (HSIC) New CEO Pick And Exclusive CitoCBC Deal - simplywall.st
Henry Schein Shares Consolidate as Technical and Fundamental Catalysts Align - AD HOC NEWS
Henry Schein sets early Feb. 24 webcast on Q4 2025 results - Stock Titan
Dilation Capital Management LP Invests $5.11 Million in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein Names Frederick M. Lowery as Chief Executive Officer - Zenopa
Henry Schein, Inc. (NASDAQ:HSIC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Henry Schein Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途资讯
The Truth About Henry Schein Inc: Why Wall Street Is Watching (But TikTok Barely Cares…Yet) - AD HOC NEWS
Mizuho Adjusts Price Target on Henry Schein to $81 From $74, Maintains Neutral Rating - marketscreener.com
Here's What to Expect From Henry Schein's Next Earnings Report - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX) - The Globe and Mail
Mixed Strategic Drivers Led Upslope Capital Management to Pick Henry Schein (HSIC) - Insider Monkey
Tetratherix executes global distribution & supply agreement with Henry Schein - marketscreener.com
Tetratherix Executes Global Distribution & Supply Agreement With Henry Schein - TradingView — Track All Markets
Newly listed biotech Tetratherix secures global distribution deal with US giant Henry Schein - Business News Australia
Australia's Tetratherix hits four-week high on supply deal with Henry Schein - TradingView — Track All Markets
Henry Schein (NASDAQ:HSIC) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Henry Schein names new CEO - DrBicuspid.com
Henry Schein (HSIC) Valuation Check After Exclusive CitoCBC Distribution Agreement - Yahoo Finance
Henry Schein inks exclusive U.S. distribution deal for CLIA-waived CBC system - Medical Economics
Henry Schein enters distribution agreement for CytoChip's CLIA-waived hematology analyzer - marketscreener.com
Henry Schein Enters Distribution Agreement For CytoChip’S CLIA-Waived Hematology Analyzer - TradingView — Track All Markets
Henry Schein Agrees to Distribute CytoChip's CitoCBC system - marketscreener.com
Henry Schein (HSIC) Partners with CytoChip for Exclusive Distrib - GuruFocus
Henry Schein to distribute FDA-cleared blood test system nationwide - Investing.com
Henry Schein to distribute FDA-cleared blood test system nationwide By Investing.com - Investing.com South Africa
Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer - joplinglobe.com
3 Reasons to Sell HSIC and 1 Stock to Buy Instead - Yahoo Finance
Henry Schein names a new CEO - Digital Commerce 360
JPM26: Henry Schein focuses on high-margin, high-growth business as new CEO announced - Yahoo Finance
Henry Schein extends private placement facilities to 2028 - MSN
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term - sharewise.com
Henry Schein Seeks M&A Opportunities - marketscreener.com
Henry Schein Taps Former Thermo Fisher Exec as New CEO - Modern Distribution Management
Will Henry Schein’s (HSIC) New External CEO and Governance Shift Reframe Its Leadership Narrative? - simplywall.st
Henry Schein Names Thermo Fisher Exec Fred Lowery as CEO - Medical Product Outsourcing
Frederick Lowery named new CEO of Henry Schein, effective March 2026 - Investing.com Nigeria
Leadership transition at Henry Schein: Frederick M. Lowery to take over as CEO - Dental Tribune US
Henry Schein names Frederick M. Lowery as new CEO - newsday.com
Henry Schein Appoints Frederick M Lowery as New CEO - Orthodontic Products
Henry Schein, Inc. Announces Management Changes - marketscreener.com
Henry Schein, Inc. Appoints Frederick M. Lowery as Chief Executive Officer, Effective March 2, 2026 - marketscreener.com
Henry Schein names Frederick Lowery as new CEO - libn.com
Henry Schein appoints industry veteran Frederick M. Lowery as new CEO - Oral Health Group
Henry Schein, Inc. (HSIC) Announces New CEO Appointment - GuruFocus
Henry Schein picks new CEO with significant healthcare distribution experience - MassDevice
Henry Schein (HSIC) Appoints Frederick Lowery as New CEO - GuruFocus
Henry Schein Names Frederick Lowery Chief Executive - marketscreener.com
Henry Schein appoints new CEO amid governance changes - TipRanks
Henry Schein Appoints Frederick M. Lowery as Chief Executive Officer - citybiz
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.87%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):